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Abstract The effect of methylene blue on isolated rat liver 
mitochondria in the presence and absence of chloroacetaldehyde 
was investigated. Fatty acid oxidation was inhibited by 
chloroacetaldehyde and subsequently stimulated by methylene 
blue. Assessment of tightly coupled mitochondria revealed 
decreasing respiratory control ratios induced by increasing 
concentrations of methylene blue and methylene blue provoked 
mitochondrial swelling. In uncoupled mitochondria, methylene 
blue promoted a concentration-dependent stimulation of respira-
tion. These findings provide evidence that methylene blue, the 
redox dye currently used as an antidote for encephalopathy 
associated with alkylating chemotherapy, uncouples oxidative 
phosphorylation and acts as an electron transfer mediator to 
stimulate mitochondrial respiration. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Chloroacetaldehyde (CAA) is a potent mutagen, capable of 
impairing an array of normal cellular functions [1-3]. It is a 
reactive metabolite of many industrial chemicals [4,5] and of 
the alkylating, cytostatic drugs ifosfamide (IFO) and cyclo-
phosphamide [6,7]. CAA is presumed to be neurotoxic [8-
10], and its presence is thought to potentiate I F O associated 
encephalopathies. Presently, methylene blue (MB) is prophy-
lactically or acutely used as an antidote for I F O induced en-
cephalopathy [11-14], although its mechanism of action and 
relation to CAA toxicity are undefined. Since an inhibition of 
normal hepatic fatty acid oxidation may trigger an encepha-
lopathic event [15-17], the relations between mitochondrial 
fatty acid metabolism, CAA and M B were investigated. 
The effect of M B on cellular redox status is well established. 
MB has been shown to non-enzymatically oxidize N A D H to 
N A D and reverse some of the redox state changes in ethanol-
fed animals [18-21]. Others have demonstrated its inhibition 
of aldehyde dehydrogenase in cytosol and mitochondria from 
human and rat, respectively [22,23]. However, MB induced 
alterations in mitochondrial oxidative metabolism as a conse-
quence of its redox character remain to be described. 
The present study was designed to test the hypothesis that 
CAA alters hepatic mitochondrial oxidative metabolism of 
long chain fatty acids and application of M B corrects for 
CAA induced metabolic perturbations. Since impairment of 
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hepatic (3-oxidation is a known marker of hepatotoxicity [24], 
we used isolated rat liver mitochondria and selected palmito-
yl-L-carnitine (PLC), as a substrate for [3-oxidation. It follows 
that monitoring fluctuations in fatty acid oxidation and thus, 
cellular energetics, may be useful in predicting mitochondrial 
fitness, and in turn indicate a primary step in the cascade of 
events leading to encephalopathy, which may be prevented or 
rectified due to the biophysical activity of MB. 
2. Materials and methods 
2.1. Materials 
Methylene Blue was purchased from Hansler, AG, Herisau, Swit-
zerland. All other chemicals were obtained from either Merck, Darm-
stad, Germany, or from Sigma Chemical Corp., St. Louis, MO, and 
were of the highest grade available. 
2.2. Isolation and incubation of mitochondria 
Mitochondria from the livers of male Wistar rats (200-250 g) were 
isolated as previously described [25]. Briefly, livers were quickly re-
moved from decapitated rats and immediately transferred to ice-cold 
mannitol [0.25 M]-sucrose [0.07 M] buffer (MSB). Livers were finely 
minced and EDTA [2 mmol/L] was added prior to homogenisation. 
Mitochondria were isolated by means of differential centrifugation, 
suspended in MSB at a concentration of 1 g original liver weight 
per ml and stored on ice. Protein concentrations in mitochondrial 
preparations were determined with the biuret method using bovine 
serum albumin as standard [26]. 
Oxygen consumption by intact mitochondria was measured at 37°C 
in a chamber equipped with a Clark-type oxygen electrode. Buffer for 
all mitochondrial incubations contained potassium phosphate [0.1 M], 
triethanolamine [0.1 M], magnesium sulfate [0.15 M] in addition to 
MSB, pH 7.4. 
The respiratory control ratio (RCR = state 3/state 4) in mitochon-
dria energized with succinate was used to control the quality of each 
preparation. For RCR evaluations in the presence of MB, the redox 
dye was introduced to the incubation chamber before addition of 
succinate. 
In incubations to assess the effect of CA and MB on fatty acid 
oxidation, rotenone [2 uM] was used to inhibit the oxidation of en-
dogenous NAD-linked substrates. Uncoupling of mitochondria was 
achieved by the addition of 2,4-dinitrophenol (DNP) [150 |iM[. Mi-
tochondria uncoupled with DNP were used in all experiments with 
PLC since fatty acids are potent uncouplers in themselves. Addition of 
PLC [100 u,M], allowed for the assessment of mitochondrial P-oxida-
tion. 
2.3. Mitochondrial swelling 
Experiments with freshly isolated, tightly coupled mitochondria 
were carried out in KC1 [0.175 M]-Tris-HCl [0.025 M] buffer at pH 
7.4. Approximately 0.5 mg of mitochondrial protein were diluted in 
working buffer and swelling was followed by the decrease in turbidity 
or absorbance (^520) in a Perkin Elmer Lambda 16 spectrophotom-
eter. Readings were taken every 60 s. 
2.4. Mathematical and statistical analysis 
Data were fitted to the Michaelis-Menten equation in order to 
calculate the kinetic parameters of Km and Vm^- Results are expressed 
as mean ± S.E.M. of measurements. Statistically significant differences 
between means were first evaluated by a one-way analysis of variance. 
When significant 'F-values' were obtained, within group comparisons 
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were assessed by a Student's r-test. Two-tailed probabilities of less 
than 0.05 were considered to be significant and Bonferroni criteria 
were applied, where applicable. 
3. Results and discussion 
Essential to the maintenance of normal mitochondrial func-
tion is an intact cascade of reactions resulting in the (3-oxida-
tion of fatty acids. We have observed the correlation between 
CAA and mitochondrial dysfunction. Specifically, we have 
explored the relationships between mitochondrial p-oxidation, 
CAA and subsequent exposure to MB. To assess this, un-
coupled mitochondria energized with PLC were exposed first 
to CAA [500 itM] followed by MB [1 or 2 uM]. CAA induced 
a 4-fold decrease in oxidative metabolism, while the addition 
of MB [1 uM] to the PLC+CAA mitochondrial incubation 
stimulated oxygen consumption by 2-fold. PLC+CAA incu-
bations receiving MB [2 uM] produced respiratory rates com-
parable to mitochondria respiring on substrate previous to 
CAA intoxication (Fig. 1). Since electrons from reduced MB 
are known to re-enter the electron transport chain near cyto-
chrome c, and low concentrations [2 uM] can be used to 
create a bypass of the point where antimycin A blocks elec-
tron transport [27,28], it is conceivable that CAA may exert 
its toxic effect directly on elements of the respiratory chain, 
inhibiting electron transfer at or before cytochrome c. The 
presence of MB would therefore not prevent CAA induced 
local toxicity, but rather compensate for reduced function. 
Alternatively, CAA may lead to the formation of chloracetic 
acid and chloroacetyl-coenzyme A [29] and thus, depletion of 
CoASH pools. In this event, p-oxidation would consequently 
be slowed, and MB would act not only as a shuttle for elec-
trons, but more importantly, as a donor. 
To better estimate the electron donating capacity of MB 
and subsequent flux through the respiratory chain, we ex-
posed uncoupled mitochondria, without substrate, to rote-
none [2 itM] and MB [0.5^15 itM]. A concentration-depend-
ent, saturable response to MB was realized which, when fit to 
Michaelis-Menten conditions yielded a Km of 2.2 ±0.3 |a.M 
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Fig. 1. Inhibition of p-oxidation by CAA and subsequent stimula-
tion with MB. Mitochondria in the presence of rotenone [2 LiM] 
and DNP [150 uM] with substrate PLC were sequentially exposed 
to CAA [500 uM] and MB [1 or 2 uM]. CAA induced significant 
impairment of long chain fatty acid oxidation. Addition of MB rap-
idly stimulated respiration. ***Significant difference in comparison 
with PLC (p< 0.001). A A Significant difference in comparison with 
PLC+CAA {p< 0.01). 
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Fig. 2. Stimulation of respiration by MB in uncoupled mitochon-
dria. (A) Mitochondria in the presence of rotenone [2 |xM] and 
DNP [150 uM] but absence of substrate. (B) Effect of MB on p-oxi-
dation. Mitochondria in the presence of rotenone [2 uM], DNP [150 
irM] and PLC [100 irM]. 
and P"max of 233.8 ± 8.0 nmol/min per mg protein (Fig. 2A). 
In the presence of MB+PLC, a similar relation was observed 
and the associated Km and P"max calculated values were 
4.0 ±0.7 (J.M and 2456 ±131 nmol/min-mg protein, respec-
tively (Fig. 2B). The control rate of oxidation of PLC in un-
coupled mitochondria in the presence of rotenone was 
245.7 ±15.6 nmol/min-mg protein marking a maximum 10-
fold increase in fatty acid oxidation induced by MB. Vm!aJ 
Km values indicate a 6-fold increase in the metabolic capacity 
when PLC is added to mitochondria in the presence of MB as 
compared to MB alone. 
In tightly coupled, succinate-respiring mitochondria, addi-
tion of MB resulted in an acceleration of state-4 respiration, 
resulting in the overall decrease of RCR values, indicating the 
uncoupling of oxidative phosphorylation (OXPHOS) (Fig. 3). 
Significant inhibition of OXPHOS was apparent after the ad-
dition of just 0.5 |xM MB, whereas, mitochondria exposed to 
5 u\M MB demonstrated a much stronger inhibition. Our se-
lected range of MB was based on recently published data 
reporting a mean concentration of MB [5 uM] attained in 
plasma after a single 100 mg intravenous bolus injection 
[30], a typical daily dose administered to patients receiving 
IFO. 
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To determine if ultrastructural changes induced the uncou-
pling of OXPHOS, we investigated the effect of MB on mi-
tochondrial swelling. Appreciable swelling occurred in mito-
chondria exposed to MB [5 |J.M], while mitochondria receiving 
MB [0.5, 1 or 2 |iM], were not significantly different from 
controls (Fig. 4). Since the onset of swelling occurs in mito-
chondria incubated with MB [5 uM], while inhibition of OX-
PHOS begins with just 0.5 uM MB, structural permutations, 
although supportive of the uncoupling effect, are secondary to 
MB promoted derangements in oxidative metabolism. 
Mitochondrial respiration and OXPHOS play a major role 
in cellular bioenergetics. We describe substantial modulation 
of OXPHOS and respiration in coupled and uncoupled rat 
liver mitochondria, respectively. Analysis of tightly coupled 
mitochondria provided evidence that sub-micromolar concen-
trations of MB could significantly impair OXPHOS. Higher 
concentrations, in the range attainable in plasma, uncouple 
OXPHOS and induce mitochondrial swelling. In uncoupled 
mitochondria, MB effectively stimulates respiration in the 
presence or absence of PLC or CAA, due to its multiple 
actions, namely, rapid oxidation of NADH providing reduc-
ing equivalents necessary for (3-oxidation and electron donat-
ing/shuttling capacity, with respect to the respiratory chain. 
We demonstrate empirically that CAA dramatically reduces 
mitochondrial respiratory rates and MB affects both OX-
PHOS and the oxidation of long chain fatty acids resulting 
in compensatory, increased mitochondrial respiration. It has 
not escaped our attention that MB induced stimulation of 
fatty acid oxidation may be useful in a wide variety of appli-
cations where the metabolism of long chain fatty acids is 
desired. However, whether the impairment of OXPHOS or 
|3-oxidation is an important event in the onset of IFO induced 
neurotoxicity remains to be established, but the fact that MB 
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Fig. 3. Uncoupling of oxidative metabolism by MB. RCRs for suc-
cinate were measured in tightly coupled mitochondria exposed to 
varying concentrations of MB previous to succinate and ADP addi-
tion. Significant difference in comparison to control RCR: 
*p<0.05, **/><0.01, ***p<0.001. 
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Fig. 4. MB induced mitochondrial swelling. Tracings of the change 
in absorbance [A. 520] of control mitochondria (filled circles), and 
those in the presence of MB [5 |xM] (open circles). Incubations with 
MB [0.5, 1 or 2 uM] were not significantly different from control 
and thus do not appear in the figure. MB [5 uM] (/>< 0.001) in 
comparison to control. 
is currently used to protect from or acutely treat encephalo-
pathic events implies an important link. 
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